

Novartis Ireland Ltd

Vista Building, Elm Park Business Campus Merrion Road Dublin 4 D04 A9N6 Ireland

Telephone +353-1-2601255

June 19th 2023

NOTIFICATION OF SUPPLY SHORTAGE

HYCAMTIN® (topotecan) 1MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION (MA EU/1/96/027/005)
HYCAMTIN® (topotecan) 4MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION (MA EU/1/96/027/003)

Dear Healthcare Professional,

As distributer of Hycamtin® (topotecan) in Ireland of behalf of Sandoz DD, the new Marketing Authoristation Holder (MAH), Novartis regret to inform you of a long-term interruption to the supply of Hycamtin® 1mg and 4mg powder for concentrate for solution for infusion, due to the imminent closure at the 3rd party production facility.

Pack Strength	Date of Expected Shortage	Date of Expected availability of stock
HYCAMTIN® 1MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION	13 th April 2023	Q2 2025
HYCAMTIN® 4MG POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION	30 th August 2023	Q2 2025

Novartis are investigating the possibility of acquiring stock through other sources to maintain continuity of supply for patients, however the closure of the 3rd party production facility has affected global supplies. Please contact the HPRA or IPU websites for any updates as we will endeavour to update here if or as soon as we have further information.

Supply Queries and Medical Information:

For queries related to product availability please Nazar Charyyev at the following email address: Nazar.charyyev@novartis.com.

For medical related queries please contact the MAH at: farmacija.lek@sandoz.com. Alternatively, please contact: medinfo.dublin@novartis.com.

For further information on Hycamtin® please refer to the full summary of product characteristics (SmPC) on www.medicines.ie.

Yours sincerely,

-DocuSigned by:

Agron Hasani M.D.

agron Hasani

Country Head of Medical Affairs/Chief Medical Officer

Novartis Ireland Limited